Pulmonx Corporation 2025 Annual Report – Key Investor Takeaways

Overview

Pulmonx Corporation has released its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The report provides significant insight into the company’s financial health, business strategy, risk factors, and future outlook. The following is a detailed breakdown of key points, potential price-sensitive details, and information critical for shareholders and investors.

Key Financial and Corporate Highlights

• Public Float and Share Count: As of March 3, 2026, Pulmonx had 42,237,203 shares of common stock outstanding. The aggregate market value of voting and non-voting common equity held by non-affiliates was approximately \$101.4 million, based on the closing price on The Nasdaq Stock Market as of June 30, 2025.
• Listing: The company’s common stock trades on The Nasdaq Stock Market under the ticker symbol “LUNG”.
• Filer Status: Pulmonx is a non-accelerated filer, a smaller reporting company, and is not an emerging growth company.
• Internal Control: The company did not receive an auditor attestation on internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act for this period.

Business Overview & Strategic Focus

Pulmonx is focused on designing, developing, manufacturing, and marketing innovative products for patients with severe chronic obstructive pulmonary disease (COPD) and emphysema. The company’s main product, the Zephyr Endobronchial Valve (“Zephyr Valve”), is central to its business and is currently marketed for limited indications.

• The company expects future growth through expanded sales and marketing efforts, and by increasing adoption of its solution by hospitals, physicians, and patients.
• There are ongoing efforts to broaden the regulatory indications and market acceptance of the Zephyr Valve.
• Pulmonx continues to pursue regulatory approvals and certifications for new products and expanded use of the Zephyr Valve.

Potentially Price-Sensitive Information and Risks

1. Ongoing Losses and Path to Profitability

• Pulmonx has a history of significant net losses and expects these losses to continue. Achieving sustained profitability remains a challenge, which could impact share price if growth expectations are not met.

2. Reliance on a Single Product

• The company’s fortunes are closely tied to the commercial success of the Zephyr Valve. Failure to expand its indications or increase market adoption could adversely affect Pulmonx’s financial performance and, consequently, the stock price.

3. Regulatory and Market Risks

• Delays or failures in obtaining regulatory approvals for current or future products could materially impact the business.
• Market acceptance of the Zephyr Valve by hospitals, physicians, and patients is essential for revenue growth. Resistance to adopting new treatment methods could limit growth prospects.

4. Cybersecurity and Operational Risks

• Any compromise of information technology systems, including those supporting the LungTraX Platform and clinical trials, could result in significant operational disruptions, reputational harm, loss of business, and potential legal liabilities.

5. Fluctuating Financial Results

• Pulmonx notes its operating results may fluctuate significantly, making future results unpredictable and possibly falling below market expectations.

6. Legal and Intellectual Property Risks

• The company may face costly intellectual property litigation, infringement claims, or administrative proceedings, which could interfere with its ability to market and sell products.

7. Healthcare Reform and Regulatory Landscape

• Changes in U.S. and international healthcare policies, including the Affordable Care Act and related reforms, could affect reimbursement rates, access, and profitability for Pulmonx’s products.
• Increasing transparency and reporting requirements (such as Open Payments) regarding interactions with healthcare professionals could add compliance costs and scrutiny.

8. Management and Personnel

• Retention and hiring of senior management and highly qualified personnel is critical. Loss of key individuals could disrupt operations and impact investor confidence.

9. Competition

• The development, regulatory approval, efficacy, and commercialization of competing products and technologies could impact Pulmonx’s market share and growth prospects.

Special Note Regarding Forward-Looking Statements

The report contains numerous forward-looking statements regarding Pulmonx’s business strategy, future performance, and market outlook. These are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those projected. Investors are strongly urged to review the “Risk Factors” section in full before making investment decisions.

Important Shareholder Information

• Shareholders should be aware that Pulmonx expects to continue operating at a net loss for the foreseeable future.
• The company’s future is highly dependent on the Zephyr Valve’s success and market expansion.
• Regulatory, operational, and cybersecurity risks could significantly impact performance.
• Large swings in operating results and potential legal challenges could affect share value.
• Ongoing and upcoming healthcare reforms may alter the reimbursement landscape and add compliance costs.

Conclusion

Pulmonx Corporation’s 2025 Annual Report presents both opportunities and significant risks for investors. The company’s reliance on a single core product, its ongoing net losses, and a dynamic regulatory and competitive environment are all key factors that could drive future share price volatility. Investors are encouraged to closely monitor regulatory developments, market adoption rates, and the company’s ability to manage cybersecurity and operational risks.

Disclaimer: This article is intended for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and review the full Annual Report and risk factors before making investment decisions. The information above is derived from the company’s 2025 Annual Report and is based on public disclosures as of the date of the report.

View Pulmonx Corp Historical chart here